Clinical Trials Browser

tisotumab vedotin × Gynecologic × Clear all

NCT03786081 2026-03-13

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Phase 1/2 Active not recruiting

Uterine Cervical Neoplasms

NCT06459180 2026-03-13

TroFuse-020

Phase 3 Recruiting

Uterine Cervical Neoplasms

NCT04697628 2026-02-24

innovaTV 301

Phase 3 Completed

502 enrolled 18 charts 1 FDA

Uterine Cervical Neoplasms

NCT03438396 2023-07-25

A Trial of Tisotumab Vedotin in Cervical Cancer

Phase 2 Completed

102 enrolled 20 charts 1 FDA

Uterine Cervical Neoplasms

NCT03657043 2023-05-06

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Phase 2 Completed

98 enrolled 30 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03913741 2022-06-23

innovaTV 206

Phase 1/2 Completed

Uterine Cervical Neoplasms

NCT02001623 2021-12-29

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Phase 1/2 Completed

195 enrolled 51 charts

GastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT03245736 2021-11-04

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Phase 2 Completed

5 enrolled 8 charts

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT02552121 2021-04-08

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

Phase 1/2 Completed

33 enrolled 70 charts

GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms